Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer.
Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639. doi: 10.1177/17588359211049639. eCollection 2021.
Ther Adv Med Oncol. 2021.
PMID: 34616492
Free PMC article.
METHODS: Analyses were performed using aggregate data from the PRIMA trial and patient-level data from a subset of patients from the PAOLA-1 trial that met surgery and staging eligibility criteria of PRIMA. ...RESULTS: A total of 595/806 (266/387 HRD-positive) PAOLA …
METHODS: Analyses were performed using aggregate data from the PRIMA trial and patient-level data from a subset of patients from the PAOL …